Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | muscleblind-like splicing regulator 1 | Starlite/ChEMBL | No references |
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0026 | 0.0949 | 1 |
Echinococcus multilocularis | GPCR, family 2 | 0.0019 | 0.0518 | 0.0518 |
Echinococcus granulosus | hypothetical protein | 0.0111 | 0.5947 | 0.5947 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.2936 | 0.2551 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0026 | 0.0949 | 0.5 |
Toxoplasma gondii | exonuclease III APE | 0.0026 | 0.0949 | 0.5 |
Onchocerca volvulus | Putative neutral sphingomyelinase | 0.012 | 0.6433 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0026 | 0.0949 | 1 |
Echinococcus multilocularis | muscleblind protein 1 | 0.018 | 1 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.7871 | 0.7755 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.1817 | 0.137 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.2936 | 0.2551 |
Echinococcus granulosus | muscleblind protein | 0.018 | 1 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.7871 | 0.7755 |
Echinococcus multilocularis | muscleblind protein | 0.018 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0026 | 0.0949 | 1 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0518 | 0.0518 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0026 | 0.0949 | 0.5 |
Echinococcus multilocularis | neutral sphingomyelinase | 0.012 | 0.6433 | 0.6433 |
Schistosoma mansoni | ap endonuclease | 0.0026 | 0.0949 | 0.1475 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0026 | 0.0949 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0026 | 0.0949 | 0.0949 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0026 | 0.0949 | 0.0949 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.2936 | 0.2551 |
Loa Loa (eye worm) | hypothetical protein | 0.012 | 0.6433 | 0.6238 |
Schistosoma mansoni | ap endonuclease | 0.0026 | 0.0949 | 0.1475 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.1817 | 0.137 |
Brugia malayi | Endonuclease/Exonuclease/phosphatase family protein | 0.012 | 0.6433 | 0.6238 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0518 | 0.0805 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0026 | 0.0949 | 0.5 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0518 | 0.0518 |
Echinococcus multilocularis | conserved hypothetical protein | 0.0111 | 0.5947 | 0.5947 |
Echinococcus granulosus | expressed conserved protein | 0.0111 | 0.5947 | 0.5947 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0026 | 0.0949 | 0.5 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0518 | 0.0518 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.1817 | 0.2824 |
Echinococcus multilocularis | expressed conserved protein | 0.0111 | 0.5947 | 0.5947 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0518 | 0.0805 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.2936 | 0.2551 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0026 | 0.0949 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0026 | 0.0949 | 0.5 |
Schistosoma mansoni | neutral sphingomyelinase | 0.012 | 0.6433 | 1 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0518 | 0.0518 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0026 | 0.0949 | 0.0455 |
Echinococcus granulosus | GPCR family 2 | 0.0019 | 0.0518 | 0.0518 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0026 | 0.0949 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0026 | 0.0949 | 0.5 |
Echinococcus granulosus | neutral sphingomyelinase | 0.012 | 0.6433 | 0.6433 |
Mycobacterium leprae | PROBABLE BACTERIOFERRITIN BFRA | 0.001 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0518 | 0.0805 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0026 | 0.0949 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0518 | 0.0805 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0026 | 0.0949 | 0.0455 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0026 | 0.0949 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.7871 | 0.7755 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7079 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 3.1623 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 8.2753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 14.7157 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (binding) | = 17.7828 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (binding) | 19.9526 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.